ClinicOpinion | DOI: https://doi.org/10.31579/2835-8295/011
Role of Sglt2 Inhibitors in Modern Medicine
- Shail Jani 2
- Sagar Solanki 2
- Twinkle Rana 2
- Hardik Chaudhary 2
- Farhan Piprani 2
- Mayur Patel 3
- Vivek Solanki 3
- Parth Rathva 3
- Amit Vidja 3
- Krunal Patel 3
- Jayesh Trivedi 3
1Hod and Professor in Genreal Medicine Gaims Bhuj, India.
3rd Year Resident –General Medicine –Gaims Bhuj, India.
2rd Year Resident –General Medicine –Gaims Bhuj, India.
*Corresponding Author: Jayesh Trivedi, Hod and Professor in Genreal Medicine Gaims Bhuj, India.
Citation: Aamir Jalal Al-Mosawi (2023), Role of Sglt2 Inhibitors in Modern Medicine, International Journal of Clinical Research and Reports, 2(1); DOI:10.31579/2835-8295/011
Copyright: © 2023, Jayesh Trivedi. This is an open-access artic le distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 09 January 2023 | Accepted: 20 January 2023 | Published: 26 January 2023
Keywords: general medicine; chronic kidney; cardicac failure
Abstract
SGLT2 inhibitor is a new invention in medical practice which has changed the progress and treatment part of life threatning medical conditions like type 2 diabetes mellitus causing chronic kidney disease and end stage renal disease, it has changed the concept of treatment of cardicac failure also with compromised left ventricular ejection fraction and retained left ventricular ejection fraction, in combination of dpp4 inhibitor and metformin as a part of polypill it has shown great results with compliance and economy in control of diabetes mellitus, it does not give rise to exhaustion of islets of beta cells of langerhans as it does not affect the endocrinal function of the pancreas and this combination controls hba1c drastically(1.2)without causing hypoglycemia, thus it becomes a treatment of choice in triple drug therapy as an alternative to glp1 receptor agonist ,it can be given in dual therapy treatment, so in cases of diabetes mellitus type 2 with lv dysfunction this becomes a treatment of choice
References
- Kalyani RR, Lazo M, Ouyang P et al. (2013), Gender differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2013 Oct 31.
View at Publisher | View at Google Scholar - Haffner SM, Lehto S, Ronnemaa T, et al. (1998), Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med; 339(4):229–34.
View at Publisher | View at Google Scholar - Bell DS. (2003), Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care; 26(8):2433–2441.
View at Publisher | View at Google Scholar - Arow M., Waldman M., Yadin D., Nudelman V., Shainberg A., Abraham N. G. et al. (2020), Sodium–glucose cotransporter 2 inhibitor Dapaglifozin attenuates diabetic cardiomyopathy. Cardiovasc. Diabetol.
View at Publisher | View at Google Scholar - Briasoulis A., Al Dhaybi O. and Bakris G. L. (2018), SGLT2 inhibitors and mechanisms of hypertension. J. Curr. Cardiol. Rep. 19, 20–40
View at Publisher | View at Google Scholar - DeFronzo R. A. (2017), Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes. Metab.
View at Publisher | View at Google Scholar - Dziuba J., Alperin P., Racketa J., Iloeje U., Goswami D., Hardy E. et al. (2014), Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes. Metab.
View at Publisher | View at Google Scholar
